


# Cancer Risk Evaluation

Methods and Trends

Edited by Günter Obe, Burkhard Jandrig,  
Gary E. Marchant, Holger Schütz,  
and Peter M. Wiedemann



 WILEY-  
BLACKWELL

# **Contents**

**[Cover](#)**

**[Related Titles](#)**

**[Title Page](#)**

**[Copyright](#)**

**[Preface](#)**

**[List of Contributors](#)**

**[Chapter 1: Introduction](#)**

**[References](#)**

## **[Part One: Models and Approaches](#)**

**[Chapter 2: Models of Cancer Development: Genetic and Environmental Influences](#)**

**[2.1 Introduction](#)**

**[2.2 Specific Characteristics of Tumors](#)**

**[2.3 Tumorigenesis as a Multistep Process](#)**

**[2.4 Epigenetic Changes in Cancer Development](#)**

**2.5 miRNAs and Cancer**

**2.6 Cancer Stem Cells**

**2.7 Cancer and the Environment**

**2.8 Systems Analysis of Cancer**

**2.9 Outlook**

**References**

## **Chapter 3: Endogenous DNA Damage and Its Relevance for the Initiation of Carcinogenesis**

**3.1 Introduction**

**3.2 Types and Generation of Oxidative DNA Modifications**

**3.3 Repair of Endogenous DNA Modifications**

**3.4 Basal Steady-State Levels**

**3.5 Contribution of Endogenous DNA Modifications to Cancer Risk**

**References**

## **Chapter 4: The IARC Monographs Programme: Cancer Hazard Identification as a First Step in Cancer Risk Assessment and Cancer Prevention**

**4.1 Introduction**

**4.2 Formaldehyde, Nasopharyngeal Cancer, and Leukemia: Evolution in Evaluation**

**4.3 Herbal Medicines, Aristolochia Plant Species, and Aristolochic Acid Nephropathy**

**4.4 Concluding Remarks**

**Acknowledgment**

**References**

## **Part Two: Epidemiological Research**

### **Chapter 5: The Role of Epidemiology in Cancer Risk Assessment of Nonionizing Radiation**

**5.1 Introduction**

**5.2 Brief Outline of Common Epidemiological Study Designs**

**5.3 Criteria for Evaluating the Plausibility of Epidemiological Findings**

**5.4 Bias and Errors in Epidemiological Studies**

**5.5 Compatibility between Study Findings and Time Trends in the Occurrence of Disease**

**5.6 Discussion**

**References**

### **Chapter 6: The Role of Epidemiology in Cancer Risk Assessment of Ionizing Radiation**

**6.1 Introduction**

**6.2 Japanese Atomic Bomb Survivors**

**6.3 Medical Exposures**

**6.4 Occupational Exposures**

**6.5 Environmental Exposures**

**6.6 Conclusions**

**References**

## **Part Three: Animal Studies**

### **Chapter 7: Animal Studies on RF EMF Cancer Effects**

**7.1 Introduction**

**7.2 Exemplary Carcinogenicity Studies  
Testing the Possible Health Effects Related  
to Mobile Telephones and Base Stations  
(PERFORM-A)**

**7.3 Research Gaps**

**7.4 Proposed Research Strategy**

**7.5 Summary**

**References**

### **Chapter 8: Animal Studies in Carcinogen Identification: The Example of Power Frequency (50/60 Hz) Magnetic Fields**

**8.1 Introduction**

**8.2 Strengths and Limitations of  
Epidemiology Studies of EMF as a Cancer**



**Hazard**

**8.3 Strengths and Limitations of  
Experimental Studies of EMF as a Cancer  
Hazard**

**8.4 Role of Mechanistic Studies in EMF  
Hazard Assessment**

**8.5 Oncogenicity Studies of EMF**

**8.6 Conclusions**

**References**

## **Part Four: Genotoxicity Studies**

### **Chapter 9: Chromosomal Aberrations in Human Populations and Cancer**

**9.1 Introduction**

**9.2 Chromosomal Aberrations and Their  
Spontaneous Frequencies in Human  
Peripheral Lymphocytes**

**9.3 Micronuclei**

**9.4 Sister Chromatid Exchanges**

**9.5 Age Dependency of CA, MN, and SCE**

**9.6 Origin of CA in HPL**

**9.7 Ionizing Radiation and Chromosomal  
Aberrations**

**9.8 CA and Cancer in Human Populations**

**References**

### **Chapter 10: Cytogenetic Studies in Mammalian Somatic Cells Exposed to**

# **Radio Frequency Radiation: A Meta-Analysis**

**10.1 Introduction**

**10.2 Materials and Methods**

**10.3 Results**

**10.4 Cytogenetic Endpoints as Biomarkers for Cancer Risk**

**10.5 Perspective from Meta-Analysis and Conclusions**

**References**

## **Part Five: Omics: A New Tool for Cancer Risk Assessment?**

### **Chapter 11: Genomics and Cancer Risk Assessment**

**11.1 Introduction**

**11.2 Tissue Material**

**11.3 Analysis Technologies**

**11.4 Outlook for Individualized Cancer Treatment**

**References**

### **Chapter 12: Transcriptomics and Cancer Risk Assessment**

**12.1 Introduction**

**12.2 Sample Preparation, Technical Issues, and Data Analysis**

**12.3 Conclusions**  
**References**

## **Chapter 13: Proteomics and Cancer Risk Assessment**

**13.1 Introduction**

**13.2 Sample Preparation and Storage: A Challenge in Clinical Settings**

**13.3 Caveats and Hurdles in Protein Analysis Using Cancer Specimens and Clinical Samples**

**13.4 Separation and Fractionation of Protein Mixtures as a Prerequisite to Proteomic Analyses and Protein Quantification**

**13.5 Identification of Proteins by Mass Spectrometry**

**13.6 Array-Based Proteome Technology in Cancer Research**

**13.7 The Present and the Future: Proteomics for Individualized Cancer Therapy**

**References**

## **Part Six: Current Use of Omics Studies for Cancer Risk Assessment**



## **Chapter 14: Omics in Cancer Risk Assessment: Pathways to Disease**

**14.1 Introduction**

**14.2 “Omics” Data in Cancer Risk Assessment**

**14.3 High-Throughput Screening**

**14.4 Discussion**

**References**

## **Chapter 15: What Have “Omics” Taught Us about the Health Risks Associated with Exposure to Low Doses of Ionizing Radiation**

**15.1 Introduction**

**15.2 Pre-“Omics”**

**15.3 Functional Genomics**

**15.4 Gene Expression Profiling for Nontargeted Effects Induced by Exposure to Ionizing Radiation**

**15.5 Gene Expression Profiling for Adaptive Responses Induced by Exposure to Ionizing Radiation**

**15.6 In Vivo Gene Profiling after Irradiation**

**15.7 Radiation-Induced Oscillatory Signaling**

**15.8 Proteomic Profiling after Exposure to Ionizing Radiation**

**15.9 Metabolomic Profiling after Exposure to Ionizing Radiation**

**15.10 Conclusions**  
**Acknowledgment**  
**References**

## **Chapter 16: Transcriptomics Approach in RF EMF Research**

**16.1 Introduction**  
**16.2 Transcriptomics in RF EMF Research**  
**16.3 Discussion**  
**References**

## **Chapter 17: Proteomics Approach in Mobile Phone Radiation Research**

**References**

# **Part Seven: Challenges for Risk Management**

## **Chapter 18: Evaluating the Reliability of Controversial Scientific Results**

**18.1 Introduction**  
**18.2 Detection of Scientific Misconduct**  
**18.3 Committee on Publication Ethics**  
**18.4 Conclusions**  
**References**

## **Chapter 19: Comparative Risk Assessment with Ionizing and**

## **Nonionizing Radiations**

**19.1 Introduction**

**19.2 Review of Different Radiation Types**

**19.3 Discussion**

**References**

## **Chapter 20: Communicating about Uncertainties in Cancer Risk Assessment**

**20.1 Introduction**

**20.2 The Concept of Uncertainty**

**20.3 Reasons for Communicating Uncertainties**

**20.4 Findings on Communicating Uncertainties**

**20.5 Explaining Inconclusive Evidence**

**20.6 Conclusions**

**References**

## **Chapter 21: The Precautionary Principle and Radio Frequency Exposure from Mobile Phones**

**21.1 Introduction**

**21.2 Background on the Precautionary Principle**

**21.3 Pros and Cons of the Precautionary Principle**

**21.4 Applying the Precautionary Principle to Radio Frequency Electromagnetic Fields**

**21.5 Conclusions**  
**References**

**Index**

## ***Related Titles***

Hsu, C.-H., Stedeford, T. (eds.)

**Cancer Risk Assessment  
Chemical Carcinogenesis, Hazard Evaluation, and  
Risk Quantification**

2010

ISBN: 978-0-470-23822-6

Wiedemann, P. M., Schütz, H. (eds.)

**The Role of Evidence in Risk Characterization  
Making Sense of Conflicting Data**

2008

ISBN: 978-3-527-32048-6

*Edited by*  
*Günter Obe, Burkhard Jandrig, Gary E. Marchant,*  
*Holger Schütz, and Peter M. Wiedemann*

## **Cancer Risk Evaluation**

Methods and Trends

 **WILEY-BLACKWELL**



## **The Editors**

### ***Prof. Dr. Günter Obe***

Ret. from University Duisburg-Essen

Present address:

Gershwinstrasse 33

14513 Teltow

Germany

### ***Dr. Burkhard Jandrig***

Max-Delbrück-Center

for Molecular Medicine (MDC)

Robert-Rössle-Str. 10

13125 Berlin

Germany

### ***Prof. Dr. Gary E. Marchant***

S. Day O'Connor College of Law

Arizona State University

Tempe, AZ 85287-796

USA

### ***Dipl. Päd. Holger Schütz***

Research Center Jülich, Inst.

of Neuroscience and Medicine (INM-8)

52425 Jülich

Germany

### ***Prof. Dr. Peter M. Wiedemann***

Karlsruher Institut für Technologie (KIT)

TAB - Büro für Technikfolgen-

Abschätzung beim Deutschen Bundestag

Neue Schönhauser Straße 10

10178 Berlin

Germany

### **Cover**

Microscopic Cancer Cell # PhotoDisc/Getty Images

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty can be created or extended by sales representatives or written sales materials. The Advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

**Library of Congress Card No.:** applied for

**British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

**Bibliographic information published by the Deutsche Nationalbibliothek**

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2011 Wiley-VCH Verlag & Co. KGaA,

Boschstr. 12, 69469 Weinheim, Germany

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical, and Medical business with Blackwell Publishing.

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**ISBN:** 978-3-527-32753-9

**ePDF ISBN:** 978-3-527-63462-0

**ePub ISBN:** 978-3-527-63463-7

**Mobi ISBN:** 978-3-527-63464-4

**oBook ISBN:** 978-3-527-63461-3

# ***Preface***

Both the modern biomedical research such as genomics and proteomics and the rapid advances in high-throughput screening molecular technologies have revolutionized the knowledge about functional and regulatory genomics, which is beginning to make an immense impact on our understanding of human health and disease. These developments have also brought great hope to improve cancer risk assessment, even to solve scientific controversies about cancer risk claims, such as the debate whether electromagnetic fields from mobile telephony cause cancer in humans.

During the past few years, we were able to focus on this question in an integrated multidisciplinary research project on the implications of modern biomedicine on risk assessment (IMBA), sponsored by the Helmholtz Association of German Research Centres. As a health technology assessment project, IMBA analyzed how new developments in biomedicine, which are often summarized under the term “toxicogenomics,” will transform the present risk management framework. IMBA looked into a wide range of scientific and social challenges that deserve careful attention, particularly on issues related to risk assessment, risk perception, and risk communication.

In 2008, we organized an international workshop in Berlin as part of the IMBA project. The aim of the workshop was to compare the potential of genomics and traditional approaches used in cancer risk assessment, particularly genotoxicity studies, with regard to their potential to inform assessment of unclear risks, that is, risks where evidence is insufficient for a conclusive risk assessment. The unclear risks chosen for discussion were radio frequency electromagnetic fields. Topics such as the validity and reliability of genotoxic research for cancer risk assessment, the prospects of toxicity testing and risk assessment, and

the implications for policy making were critically reviewed and evaluated by experts in the fields of ionizing and nonionizing radiation, genotoxicity, molecular medicine, and epidemiology.

The discussions during the workshop motivated us to plan a publication on these topics. Further impetus came from the ongoing societal debate on the health implications of electromagnetic fields, which seems not to be solved but stimulated by new molecular biomarker studies and high-throughput technologies in this field. We think that in a climate of excitement about the promises of molecular medicine, it is crucial to explore the validity of molecular biomarkers and evaluate their added value for risk assessment. We hope that this book will contribute to effective interdisciplinary communication and collaboration in the fields of molecular biology, cancer research, risk assessment, and public health policy.

We are grateful to all authors of the book for investing their valuable time in writing their contributions and participating in the review process in order to make the book valuable for all readers. Last but not least, we appreciate the support of the Helmholtz Association of German Research Centres.

*Günter Obe, Burkhard Jandrig,  
Gary E. Marchant, Holger Schütz,  
Peter M. Wiedemann*

Berlin, December 2010

# ***List of Contributors***

## ***Robert A. Baan***

WHO-International Agency for Research on Cancer  
The IARC Monographs Programme  
150, cours Albert Thomas  
69372 Lyon Cedex 08  
France

## ***Gabriele Berg-Beckhoff***

Unit for Health Promotion Research  
Institut of Public Health  
University of Southern Denmark  
Niels Bohrs Vej 9  
6700 Esbjerg  
Denmark

## ***Maria Blettner***

Johannes Gutenberg-University of Mainz  
Institute of Medical Biostatistics,  
Epidemiology, and Informatics  
Obere Zahlbacher Straße 69  
55101 Mainz  
Germany

## ***Jochen Buschmann***

Fraunhofer Institute for Toxicology and Experimental  
Medicine  
Department of Toxicology & Environmental Hygiene  
Nikolai-Fuchs-Strasse 1  
30625 Hannover  
Germany

## ***Vincent J. Cogliano***



Acting Director, Integrated Risk  
Information System (IRIS)  
National Center for Environmental Assessment  
U.S. Environmental Protection Agency  
1200 Pennsylvania Ave NW (8601P)  
Washington DC 20460  
USA

***Clemens Dasenbrock***

Fraunhofer Institute for Toxicology and Experimental  
Medicine  
Department of Toxicology & Environmental Hygiene  
Nikolai-Fuchs-Strasse 1  
30625 Hannover  
Germany

***Marco Durante***

GSI Helmholtzzentrum für Schwerionenforschung  
Biophysics Department  
Planckstrasse 1  
64291 Darmstadt  
Germany

and

Technical University of Darmstadt  
Department of Condensed Matter Physics  
Hochschulstraße 3  
46289 Darmstadt  
Germany

***Bernd Epe***

University of Mainz  
Institute of Pharmacy and Biochemistry  
Staudingerweg 5  
55128 Mainz

Germany

***Markus Fußer***

University of Mainz

Institute of Pharmacy and Biochemistry

Staudingerweg 5

55128 Mainz

Germany

***Burkhard Jandrig***

Max Delbrück Center for Molecular Medicine

Robert-Rössle-Str. 10

13125 Berlin

Germany

***Wolfgang Kemmner***

Max Delbrück Center for Molecular Medicine

Experimental and Clinical Research

Center (ECRC)

Research Group Surgical Oncology

Robert-Rössle-Str. 10

13125 Berlin

Germany

***Jürgen Kiefer***

Universität Giessen

Am Dornacker 4

35435 Wettenberg

Germany

***Alexander Lerchl***

Jacobs University Bremen

School of Engineering and Science,

Research II

Campus Ring 6

28759 Bremen

Germany

***Dariusz Leszczynski***

STUK - Radiation and Nuclear Safety  
Authority  
Laippatie 4  
00881 Helsinki  
Finland

***David C. Lloyd***

Health Protection Agency  
Chilton  
Didcot OX11 0RQ  
UK

***Gary E. Marchant***

Arizona State University Sandra  
Day O'Connor College of Law  
P.O. Box 877906  
Tempe, AZ 85287-796  
USA

***David L. McCormick***

IIT Research Institute  
10 West 35th Street  
Chicago, IL 60616  
USA

***Meike Mevissen***

University of Bern Vetsuisse Faculty  
Department of Clinical Research and Veterinary Public  
Health  
Division Veterinary Pharmacology and Toxicology  
Länggassstrasse 124  
3012 Bern  
Switzerland

***William F. Morgan***

Pacific Northwest National Laboratory  
Cell Biology and Biochemistry  
P.O. Box 999, MSIN P7-56  
Richland, WA 99354  
USA

***Günter Obe***

Ret. from University Duisburg-Essen  
Present address:  
Gershwinstrasse 33  
14513 Teltow  
Germany

***Christopher J. Portier***

National Center for Environmental  
Health/Agency for Toxic Substances  
and Disease Registry  
Centers for Disease Control  
and Prevention  
1600 Clifton Road  
Atlanta, GA 30333

***Thomas J. Prihoda***

University of Texas Health Science Center  
Department of Pathology  
San Antonio, TX 78229  
USA

***Brigitte Schlehofer***

German Cancer Research Centre  
Unit of Environmental Epidemiology  
Im Neuenheimer Feld 280  
69120 Heidelberg  
Germany

***Alexander Schramm***

Universitätsklinikum Essen, Pädiatrie III  
Onkologisches Labor  
Hufelandstr. 55  
45122 Essen  
Germany

***Holger Schütz***

Research Center Jülich  
Institute of Neuroscience and Medicine (INM-8)  
52425 Jülich  
Germany

***Joachim Schüz***

International Agency for Research on Cancer (IARC)  
Section of Environment and Radiation  
150, cours Albert Thomas  
69372 Lyon Cedex 08  
France

***Michal R. Schweiger***

Max-Planck Institute for Molecular Genetics  
Department of Vertebrate Genomics  
Innestrasse 63-73  
14195 Berlin  
Germany

***Marianne B. Sowa***

Pacific Northwest National Laboratory  
Cell Biology and Biochemistry  
P.O. Box 999, MSIN P7-56  
Richland, WA 99354  
USA

***Reuben Thomas***

National Institute of Environmental Health Sciences

Laboratory of Toxicology and Pharmacology  
Environmental Systems Biology  
P.O. Box 12233, MD B2-08  
Research Triangle Park, NC 27709  
USA

***Bernd Timmermann***

Max-Planck Institute for Molecular Genetics  
Ihnestrasse 63-73  
14195 Berlin  
Germany

***Vijayalaxmi***

University of Texas Health Science Center  
Department of Radiology  
San Antonio, TX 78229  
USA

***Richard Wakeford***

The University of Manchester  
Dalton Nuclear Institute  
Pariser Building - G Floor  
P.O. Box 88, Sackville Street  
Manchester M60 1QD  
UK

***Peter M. Wiedemann***

Karlsruher Institut für Technologie (KIT)  
TAB - Büro für Technikfolgen-Abschätzung beim Deutschen  
Bundestag  
Neue Schönhauser Straße 10  
10178 Berlin  
Germany



# ***Chapter 1***

## ***Introduction***

Cancer is one of the leading causes of human mortality. Over the past 30 years, the global burden of cancer has more than doubled. According to the recent World Cancer Report, published by the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), in 2008 there were 7 million deaths from cancer. Affected by the still growing and aging world population, this figure is expected to increase to 17 million annually by 2030 [1]. While many environmental cancer risk factors, such as exposures to ionizing radiation or tobacco smoke, alcohol consumption, or excessive sun exposure, have been established [2], assessments of cancer hazards and risks are difficult and often highly uncertain. Of the more than 900 agents that have been evaluated by IARC, only 12% have been classified as being clearly carcinogenic to humans [3]. And even if an agent has been identified as a carcinogen, the risk it poses to a given population is often hard to estimate. The reasons for these difficulties are manifold. First of all, there are different types of cancer that differ in their etiology. Another reason - and that is the focus of this book - is that cancer causation is hard to investigate. Experimental studies in humans are for obvious ethical reasons not possible, thus cancer risk assessment has to rely on indirect evidence.

At present, assessments of carcinogenicity are based on three pillars: epidemiological studies in humans, studies in experimental animals, and genotoxicity studies. Epidemiological studies aim at identifying the causes of

cancer by studying the covariation between exposure to an agent and cancer incidence. Although there is a long debate on if and when epidemiology actually can provide causal evidence [4], there is little disagreement that epidemiological studies are the most important source of knowledge for cancer risk assessment [2, 5]. In studying the carcinogenicity of agents, epidemiological studies have to rely on given exposures to the respective agents, for instance, radon emanating from the soil or electromagnetic fields emitted from mobile communication devices. These conditions are usually not under control of the investigators, and although epidemiologists have developed an elaborate methodology to match specific study demands [6], problems such as bias and confounding frequently limit the conclusiveness of their results.

Compared to epidemiology, animal studies have the advantage of permitting experimental designs, where (at least in principle) everything can be controlled. This allows the most stringent test of a causal relationship between the exposure to an agent and an adverse effect. At least for chemical agents, there is a kind of “gold standard” that is used for carcinogenicity testing, which includes 2-year studies with rodents [7]. However, these studies are time consuming and expensive, limiting the number of agents that are tested [2]. Beside ethical considerations regarding the use of animals in research, the appropriateness of animal models for investigating and predicting human diseases has been disputed [8]. It should also be noted that this gold standard is not so well established for some physical agents. For example, many animal studies investigating the potential carcinogenicity of radio frequency electromagnetic fields (RF EMF) use only one type of animals and often for a short period [9]. An important limitation of using animal studies for carcinogenicity testing is that the experimental results always have to be

extrapolated to humans, which is of course acknowledged in evaluations of evidence for cancer risk assessment [2, 5].

Basically, the same holds for genotoxicity studies, where experimental findings also have to be evaluated with regard to their implications for humans. Their value lies in the fact that cancer results primarily from genetic changes in single cells. Therefore, agents that are able to damage cellular DNA lead to mutations and then possibly to cancer. For instance, people exposed to ionizing radiation have both an elevated cancer risk and elevated frequencies of chromosomal aberrations in their peripheral lymphocytes, showing the mutagenic activity of ionizing radiation. Mutations are initiating events for the development of cancer and therefore testing of various agents for their possible mutagenicity is an important part of cancer risk assessment [10].

Over the past years, new technologies have been developed that promise new insight into cancer risk assessment by focusing on the role of the genome for understanding cancer initiation and development [11, 12]. These so-called omics technologies include genomics for DNA variations, transcriptomics for messenger RNA, proteomics for peptides and proteins, and metabolomics for intermediate products of metabolism. Technological breakthroughs allow simultaneous examination of thousands of genes, transcripts, proteins, and metabolites with high-throughput techniques and analytical tools to extract information. These new technologies are expected to provide a highly sensitive detection of low-dose effects, more reliable extrapolation of risk estimates across doses, routes, and species, and valuable insight into the mechanism of action of toxicants. Overall, the ability to classify chemicals and other stressors based on their effects at omics level would permit the development of new testing strategies in cancer risk assessment. At present, genomics-

and transcriptomics-based approaches are most promising, while metabolomics, though in principle quite potent, is quite nascent in its development, as present techniques and the methodology are far away from inspecting the whole metabolome. High-throughput screening technologies have their own technical limitations and uncertainties. The transcriptome and proteome are highly dynamic and change rapidly and dramatically in response to perturbations or even during normal cellular events. The modern screening technologies still have the problem of reproducibility and variability between studies and are prone to produce false positive results [13, 14].

An important aspect here is quality control of scientific investigations. Although in general not limited to the omics field, the huge amount of data produced with microarray experiments and the extensive data processing required for analysis make open data accessibility to allow independent reevaluation of findings an important claim, which is increasingly acknowledged in the scientific community [15, 16]. Another aspect of quality control is how to evaluate the reliability of controversial scientific results. As said before, it is difficult to rule out errors in high-throughput screening research. Even more complicated is the proper dealing with fraud suspicions. Although fraud in science is by no means a new phenomenon, recent scandals in highly prestigious scientific journals have also called the public's attention to this issue [17]. Thus, the highly welcome new approaches to cancer risk assessment also call for the establishment of rules that allow a careful evaluation of study results. Furthermore, better risk communication is required for informing health professionals, the media, and the general public about the meaning of omics findings for risk assessment [18]. A particular problem here is if and when uncertainties in risk assessment should be communicated to a nonexpert audience. On a more general level, the